ProCE Banner Activity

What Pharmacists Should Know About CAR T-Cell Therapy

Clinical Thought
As more patients are treated with CAR T-cell therapies, pharmacists in both community and academic practices are becoming essential to patient care. In this commentary, I review key topics in CAR T-cell therapy that pharmacists should know and provide recommendations for those practicing in the community and in centers authorized to administer CAR T-cell therapy.

Released: October 11, 2021

Expiration: October 10, 2022

Share

Faculty

Zahra Mahmoudjafari

Zahra Mahmoudjafari, PharmD, BCOP, DPLA

Clinical Pharmacy Manager, Blood and Marrow Transplant Program
Division of Hematological Malignancies and Cellular Therapeutics
PGY2 Oncology Residency Program Director
The University of Kansas Cancer Center
Westwood, Kansas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Zahra Mahmoudjafari, PharmD, BCOP, DPLA

Clinical Pharmacy Manager, Blood and Marrow Transplant Program
Division of Hematological Malignancies and Cellular Therapeutics
PGY2 Oncology Residency Program Director
The University of Kansas Cancer Center
Westwood, Kansas

Zahra Mahmoudjafari, PharmD, BCOP, DPLA, has disclosed that she has received consulting fees from Bristol-Myers Squibb, Coherus, GlaxoSmithKline, Incyte, Medexus, Merck, Novartis, and Omeros.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.